Archford Capital Strategies LLC Invests $1.42 Million in Sanofi $SNY

Key Points

• Archford Capital Strategies bought 33,227 Sanofi shares worth approximately $1.42 million in the second quarter, while institutional investors collectively own 14.03% of the company.
• Sanofi reported quarterly revenue of $13.36 billion, up 16% year over year, but earnings per share declined to $2.41 from $3.24 in the prior-year period.
• SNY shares were trading at $42.85, below the analyst consensus target of $49.50; Wall Street’s overall rating remains “Hold,” with ratings ranging from Strong Buy to Sell.

Archford Capital Strategies LLC bought a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 33,227 shares of the company's stock, valued at approximately $1,417,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Physician Wealth Advisors Inc. increased its holdings in Sanofi by 180.5% in the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company's stock worth $28,000 after acquiring an additional 379 shares in the last quarter. Leonteq Securities AG boosted its position in shares of Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company's stock worth $29,000 after purchasing an additional 297 shares during the period. Western Wealth Management LLC purchased a new stake in shares of Sanofi in the first quarter worth $29,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Sanofi during the 3rd quarter valued at $29,000. Finally, Palisade Asset Management LLC purchased a new position in shares of Sanofi during the 3rd quarter valued at $30,000. Hedge funds and other institutional investors own 14.03% of the company's stock.

Sanofi Trading Down 0.7%

SNY stock opened at $42.85 on Thursday. The firm has a fifty day moving average price of $43.97 and a 200 day moving average price of $44.63. Sanofi has a fifty-two week low of $40.89 and a fifty-two week high of $52.68. The firm has a market cap of $103.89 billion, a PE ratio of 22.43, a price-to-earnings-growth ratio of 1.30 and a beta of 0.35. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The company had revenue of $13.36 billion for the quarter. During the same period in the previous year, the company earned $3.24 EPS. Sanofi's revenue for the quarter was up 16.0% compared to the same quarter last year. Sell-side analysts anticipate that Sanofi will post 5.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Weiss Ratings lowered Sanofi from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, August 3rd. Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 29th. Royal Bank Of Canada started coverage on Sanofi in a research report on Tuesday. They set a "sector perform" rating for the company. Finally, Morgan Stanley set a $49.00 target price on Sanofi in a research note on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $49.50.

Sanofi Company Profile

Sanofi is a global healthcare company headquartered in France that develops, manufactures and markets prescription medicines and vaccines. Its portfolio serves patients across areas including immunology, rare diseases, rare blood disorders, neurology, oncology and inflammatory conditions, as well as other specialty-care and general-medicine categories.

The company is also a major vaccine producer through its vaccines business, which supplies products for diseases such as influenza, polio, pertussis, meningitis and dengue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.